ArticleFrontiers in oncology2021
Competing Endogenous RNA in Colorectal Cancer: An Analysis for Colon, Rectum, and Rectosigmoid Junction.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- Role of SFTPD/miR-335-5p/lnc-HNRNPUL2 axis in colorectal cancer: in silico characterization and clinical validation.BMC cancer · 2026Article
- Comprehensive pan-cancer analysis and experimental validation of mitotic arrest defective 2-like 1 (MAD2L1) in colorectal cancer.BioImpacts : BI · 2026Article
- Machine learning-based survival prediction in colorectal cancer combining clinical and biological features.Oncotarget · 2025Article
- Development and validation of nomograms for predicting survival of locally advanced rectosigmoid junction cancer patients: a SEER database analysis.Translational cancer research · 2025Article
- MicroRNA: role in macrophage polarisation and colorectal cancer pathogenesis.Frontiers in cell and developmental biology · 2025Review
- Shared and specific competing endogenous RNAs network mining in four digestive system tumors.Computational and structural biotechnology journal · 2024Article
- Comprehension of rectosigmoid junction cancer molecular features by comparison to the rectum or sigmoid colon cancer.Journal of gastrointestinal oncology · 2023Article
- Identifying the tumor location-associated candidate genes in development of new drugs for colorectal cancer using machine-learning-based approach.Medical & biological engineering & computing · 2022Article
- Pan-Cancer Analysis of BUB1B/hsa-miR-130a-3p Axis and Identification of Circulating hsa-miR-130a-3p as a Potential Biomarker for Cancer Risk Assessment.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Down-Regulated miR-130a/b Attenuates Rhabdomyosarcoma ProliferationFrontiers in molecular biosciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is a heterogeneous cancer. Its treatment depends on its anatomical site and distinguishes between colon, rectum, and rectosigmoid junction cancer. This study aimed to identify diagnostic and prognostic biomarkers using networks of CRC-associated transcripts that can be built based on competing endogenous RNAs (ceRNA).
methodsRNA expression and clinical information data of patients with colon, rectum, and rectosigmoid junction cancer were obtained from The Cancer Genome Atlas (TCGA). The RNA expression profiles were assessed through bioinformatics analysis, and a ceRNA was constructed for each CRC site. A functional enrichment analysis was performed to assess the functional roles of the ceRNA networks in the prognosis of colon, rectum, and rectosigmoid junction cancer. Finally, to verify the ceRNA impact on prognosis, an overall survival analysis was performed.
resultsThe study identified various CRC site-specific prognosis biomarkers: hsa-miR-1271-5p,
conclusionsSeveral potential prognostic markers for colon, rectum, and rectosigmoid junction cancer were found. CeRNA networks could provide better understanding of the differences between, and common factors in, prognosis of colon, rectum, and rectosigmoid junction cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.